BRAF and central nervous system cancer: These tumors are associated with shorter response durations and worse long-term outcomes compared to non-BRAF V600E gliomas.[2] The BRAF V600E mutations is an unfavorable prognostic factor in childhood gliomas leading to high rates of tumor recurrence and poor response to standard treatments.[3] Furthermore, treating pediatric gliomas presents several limitations.